CRISPR-directed exon skipping; friend or foe (opportunity or warning sign)?

Publisher of over 50 scientific journals across the life, physical, earth, and health sciences, both independently and in partnership with scientific societies including Cell, Neuron, Immunity, Current Biology, AJHG, and the Trends Journals.

Authors

Institutions

Publication Details

Journal
Molecular Therapy — Nucleic Acids
Published
2025-04-29
DOI
https://doi.org/10.1016/j.omtn.2025.102539
Citations
1
Primary Topic
CRISPR and Genetic Engineering
Type
article
Field-Weighted Citation Impact
0.81
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

CRISPR-directed exon skipping; friend or foe (opportunity or warning sign)?

Eric B. Kmiec, Kelly Banas
1 citations
Molecular Therapy — Nucleic Acids
CRISPR and Genetic Engineering
0.81
article

CRISPR-directed exon skipping; friend or foe (opportunity or warning sign)?

Eric B. Kmiec, Kelly Banas
article en
1 citations

Abstract

Publisher of over 50 scientific journals across the life, physical, earth, and health sciences, both independently and in partnership with scientific societies including Cell, Neuron, Immunity, Current Biology, AJHG, and the Trends Journals.

Molecular Therapy — Nucleic AcidsVol. 36(2)
Christiana Care Health System (US)
Openalex Percentile: Top 29%
CRISPR and Genetic Engineering
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

CRISPR-directed exon skipping; friend or foe (opportunity or warning sign)? — Eric B. Kmiec, Kelly Banas · Molecular Therapy — Nucleic Acids (2025) | TGRS Research Map | TGRS